Osteoblast and osteoclast activity in a malignant infantile osteopetrosis patient following bone marrow

Related Experiment Video

Updated: Aug 29, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Chun-Jung Chen1, Tsu-Yi Chao, Der-Ming Chu

  • 1Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China.

Journal of Pediatric Hematology/Oncology
|January 7, 2004
PubMed

Insights

Bone marrow transplantation successfully treated a child with malignant infantile osteopetrosis. Monitoring bone metabolic markers like tartrate-resistant acid phosphatase 5b (TRAcP 5b) aids in early treatment assessment.

Area of Science:

  • Pediatric Hematology
  • Genetics
  • Biochemistry

Background:

  • Malignant infantile osteopetrosis (MIO) is a rare genetic disorder characterized by impaired osteoclast function, leading to bone sclerosis.
  • Hematopoietic stem cell transplantation (HSCT) is a potential curative treatment for MIO, but early assessment of treatment efficacy is crucial.

Observation:

  • A 6-month-old boy diagnosed with MIO underwent HSCT.
  • The patient's clinical and biochemical responses were monitored post-transplantation.

Findings:

  • Successful HSCT led to a significant decrease in serum tartrate-resistant acid phosphatase 5b (TRAcP 5b) levels.
  • Bone-specific alkaline phosphatase (BAP) levels also showed changes, indicating altered bone metabolism.

Implications:

  • Serum TRAcP 5b and BAP serve as valuable biomarkers for early assessment of HSCT efficacy in MIO patients.
  • This monitoring approach can guide treatment adjustments and predict patient outcomes.
  • Further research into bone metabolic markers could refine MIO management strategies.

More Related Videos

Osteoclast Derivation from Mouse Bone Marrow06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.